ESR1 and breast cancer: To further test the clinical relevance of sample position in EMBER and the molecular pathway scores, we evaluated them for association with overall and recurrence-free survival for ER + BC patients who received only endocrine therapy (METABRIC: OS/RFS and SCAN-B: OS/RFS).